KYMR Logo

Kymera Therapeutics, Inc. (KYMR) 

NASDAQ
Market Cap
$2.63B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
411 of 960
Rank in Industry
248 of 550

Largest Insider Buys in Sector

KYMR Stock Price History Chart

KYMR Stock Performance

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat …

Insider Activity of Kymera Therapeutics, Inc.

Over the last 12 months, insiders at Kymera Therapeutics, Inc. have bought $46 and sold $58.98M worth of Kymera Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Kymera Therapeutics, Inc. have bought $18.82M and sold $68.06M worth of stock each year.

Highest buying activity among insiders over the last 12 months: BAKER BROS. ADVISORS LP (director) — $835.

The last purchase of 1 shares for transaction amount of $46 was made by BAKER BROS. ADVISORS LP (director) on 2024‑08‑20.

List of Insider Buy and Sell Transactions, Kymera Therapeutics, Inc.

2024-12-02Saledirector
2,500
0.0039%
$49.00$122,500-8.12%
2024-09-17Saledirector
13,500
0.0216%
$48.28$651,766-2.22%
2024-08-26Saledirector
5,000
0.0077%
$49.10$245,509-6.71%
2024-08-20Purchasedirector
1
<0.0001%
$46.41$46-0.13%
2024-07-16SaleChief Medical Officer
23,145
0.0578%
$45.81$1.06M-4.88%
2024-07-15SaleChief Medical Officer
16,455
0.0405%
$45.15$742,9250.00%
2024-07-09Saledirector
453,960
0.9459%
$38.21$17.35M0.00%
2024-06-13Saledirector
10,200
0.0168%
$34.98$356,796+31.86%
2024-06-12Saledirector
16,740
0.028%
$35.45$593,378+32.70%
2024-06-07Saledirector
8,500
0.0139%
$32.99$280,400+37.74%
2024-05-23SaleChief Operating Officer
2,575
0.0043%
$34.99$90,105+31.29%
2024-03-15Saledirector
71,764
0.1171%
$40.46$2.9M+3.92%
2024-03-14Saledirector
55,779
0.0861%
$39.98$2.23M+6.68%
2024-03-13Saledirector
139,255
0.2271%
$42.23$5.88M-0.50%
2024-03-13Sale10 percent owner
139,255
0.2271%
$42.23$5.88M-0.50%
2024-03-12Saledirector
162,918
0.2674%
$41.98$6.84M+0.64%
2024-03-12Sale10 percent owner
162,918
0.2674%
$41.98$6.84M+0.64%
2024-03-11Saledirector
51,184
0.0849%
$42.85$2.19M-0.47%
2024-03-11Sale10 percent owner
51,184
0.0849%
$42.85$2.19M-0.47%
2024-03-04SaleChief Financial Officer
3,934
0.0064%
$41.86$164,664-1.13%

Insider Historical Profitability

8.43%
BAKER BROS. ADVISORS LPdirector
5516986
8.5184%
$40.5410
BVF PARTNERS L P/ILdirector
2656191
4.1013%
$40.5480<0.0001%
LAMPERT MARK N
257754
0.398%
$40.5440+55.88%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
T. Rowe Price$254.55M10.326.33M+18.67%+$40.05M0.03
Baker Bros Advisors LP$241.04M9.776M0%+$01.73
Atlas Venture Life Science Advisors Llc$216.17M8.765.38M-8.21%-$19.33M20.06
Bvf Inc Il$207.5M8.415.16M0%+$01.52
The Vanguard Group$191.64M7.774.77M+19.25%+$30.93M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.